Pharmalink is a specialty pharma company whose most advanced project, Nefecon®, has the potential to considerably improve the treatment of patients with primary IgA nephropathy, an inflammatory kidney disease. Over time, around 40 percent of these patients develop renal failure, which can lead to a need for dialysis and kidney transplant.

Nefecon® has been shown to have a convincing efficacy and safety profile in an extensive European phase IIb trial. Pharmalink is now preparing for a phase III trial, expected to start at the beginning of 2017.

Nefecon® is a patented, oral formulation of budesonide that has a locally-acting and potent effect. The substance slows progression of IgA nephropathy by restricting the immune system’s overreaction, which is the underlying cause of the disease. Nefecon® has the potential to eliminate the need of dialysis and kidney transplants, and has been granted orphan drug status in the US.

Pharmalink at a glance

What they do: Develops Nefecon® – an orphan drug project in an advanced clinical phase designed to treat inflammatory kidney disease
Founded in: 2004
Headquarters: Stockholm, Sweden

By continuing to interact with the site, you agree to the use of cookies. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.